Lv4
590 积分 2024-02-03 加入
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
1小时前
已完结
Correction to Lancet Oncol 2025; 26: 367–77
1小时前
求助中
Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
4天前
已完结
Immune checkpoint inhibitors (ICIs)-related ocular myositis
11天前
已完结
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
1个月前
已完结
Correction to: “Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer”
1个月前
已完结
Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer
1个月前
已完结
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
1个月前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
1个月前
已完结
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
1个月前
已完结
皖公网安备34019202002308
